ABVC receives Australian TGA approval to initiate Phase II study of vitargus

ABVC BioPharma announced that approval to initiate the Phase II study of its Vitargus medical device, in Australia, was received from the Australian Therapeutic Goods Administration, TGA, on February 9, 2023. Vitargus is the first biodegradable vitreous substitute to facilitate retina reattachment surgery. "We are pleased to receive Vitargus Phase II study approval from Australian TGA to enable initiating the study at two prestigious Australian sites," said Dr. Howard Doong, Chief Executive Officer of the Company. "We expect the study to further demonstrate that Vitargus has properties that eliminate the need for post-surgery patient face-down positioning and can provide greater patient comfort and visual acuity during the surgical recovery period." Dr. Doong further noted that "Since Australia is recognized throughout the world for its advanced biotech research, receiving TGA approval will certainly encourage other countries to permit clinical studies of Vitargus as well."